Dana Farber Cancer Institute, Boston, MA
Catherine Curran , Gregory Russell Pond , Andres Acosta , Sarah Abou Alaiwi , Matthew D. Ingham , Mark A. Preston , Graeme S. Steele , Kerry L. Kilbridge , Bradley Alexander McGregor , Matthew Mossanen , Guru Sonpavde , Amin Nassar
Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) extends survival in muscle invasive bladder cancer (MIBC) patients (pts). Pathologic complete response (pCR) is associated with survival. We conducted a retrospective study to examine the prognostic impact of other variables including histologic subtype, location, multifocality, margins, size of tumor and toxicities. Methods: Pts who underwent RC at Dana-Farber for MIBC stage T2-T4N0-1 were studied. Data were collected for demographics, clinical and pathologic variables. Descriptive stats were reported, and Cox proportional hazards regression analyses were conducted to examine the association with recurrence-free survival (RFS) and overall survival (OS). Results: From 2002 to 2018, 150 patients were available. The median age was 66 (range 36-89) and 102 (68%) were male. MVAC/dose dense MVAC, GC and other non-standard regimens were given in 42 (28%), 85 (56.7%) and 23 (15.3%) pts, respectively. The 2-yr RFS was 63.6%, the 5-yr OS was 68.7% and pCR occurred in 38 pts (25.3%). Multivariable analysis identified pure urothelial carcinoma in the residual tumor and absence of pathologic response to be associated with poor RFS and OS. Positive margins were associated with poor RFS, while grade ≥3 toxicities were associated with poor OS. Conclusions: Pure urothelial carcinoma histology was associated with worse RFS and OS following RC after NAC for MIBC, suggesting molecular studies may be useful in these cases. The association of severe toxicities with poor OS suggests that optimal pt selection for NAC and early recognition of toxicities is important.
RFS | |||
---|---|---|---|
Path Stage at Cystectomy | pT0 | Reference | <0.001 |
pTis, pTa, pT1 | 0.87 (0.30, 2.51) | ||
pT2a-pT4 | 3.17 (1.39, 7.27) | ||
pTanyN+,pTanyM+ | 11.90 (5.16, 27.48) | ||
Margins | Positive vs Negative | 3.15 (1.38, 7.19) | 0.006 |
Histology | Pure Urothelial vs Mixed | 3.36 (1.38, 8.21) | 0.008 |
OS | |||
Path Stage at Cystectomy | pT0 | Reference | <0.001 |
pTis, pTa, pT1 | 1.77 (0.39, 7.93) | ||
pT2a-pT4 | 5.93 (1.70, 20.72) | ||
pTanyN+,pTanyM+ | 25.45 (7.22, 89.77) | ||
Histology | Pure Urothelial vs Mixed | 3.29 (1.14, 9.48) | 0.027 |
Toxicities (>Gr 3) | Yes vs. No | 2.31 (1.21, 4.41) | 0.011 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2019 Genitourinary Cancers Symposium
First Author: Yongjune Lee
2021 ASCO Annual Meeting
First Author: Raed Benkhadra
2023 ASCO Annual Meeting
First Author: Christian Pfister
2022 ASCO Annual Meeting
First Author: Elizabeth R. Plimack